Preclinical studies on the antitumor and non‐toxic effect of combining pirfenidone with vinorelbine and carboplatin in non‐small cell lung cancer DOI Open Access
Helena Branco, Catarina A. Rodrigues, Júlio Oliveira

et al.

International Journal of Cancer, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 4, 2024

Non-small cell lung cancer (NSCLC) shows limited therapeutic response to vinorelbine and carboplatin. Combining these drugs with an antifibrotic drug may enhance their antitumor effect. Pirfenidone is whose activity has been described in different types of cancer. This work aimed perform preclinical studies on the combination pirfenidone vinorelbine, or plus carboplatin, NSCLC. Our data revealed that sensitized three NSCLC lines by reducing growth, viability proliferation, inducing alterations cycle profile, increasing death (%). Importantly, increased sensitivity combined treatment (triplet) did not induce cytotoxicity against non-tumorigenic cells. Notably, triplet significantly reduced growth proliferation A-549 xenografts nude mice, as also vimentin collagen expression. Most interestingly, exhibited a safer toxicological profile than doublet (vinorelbine carboplatin) currently applied clinical practice. Altogether, support possibility repurposing carboplatin for perioperative treatment, improving efficacy while toxicity.

Language: Английский

Repurposing some of the Well-known Non-steroid Anti-inflammatory Drugs (NSAIDs) for Cancer Treatment DOI
M. Helena Vasconcelos, Andreia Palmeira, Sofia Martins Sousa

et al.

Current Topics in Medicinal Chemistry, Journal Year: 2023, Volume and Issue: 23(13), P. 1171 - 1195

Published: Jan. 31, 2023

Abstract: Drug repurposing is a strategy used to develop new treatments based on approved or in-vestigational drugs outside the scope of their original clinical indication. Since this approach bene-fits from toxicity data repurposed drugs, drug-repurposing time-saving, and inexpensive. It has higher success rate compared traditional drug discovery. Several candidates have been identified in silico screening vitro methodologies. One best examples non-steroidal anti-inflammatory (NSAIDs). Tumor-promoting inflamma-tion one hallmarks cancer, revealing connection between inflammatory processes tumor progression development. This explains why using NSAIDs context neoplasia become topic interest. Indeed, identifying with antitumor activity promising for finding novel cancer treatment opportunities. several commercial including aspirin, ibuprofen, diclofenac, celecoxib, tepoxalin cyclo- valone, naproxen, indomethacin presented activity, some them are al-ready trials treatment. However, benefits complications must be carefully evaluated, particularly patients no further therapeutic options available. review article provides insight into describes well-known that investigated as potential anticancer activity.

Language: Английский

Citations

20
Nanoarchitectonics of catalytic tubular nanomotors based on Cu/Fe@SBA-15 for lung cancer treatment DOI Creative Commons
Mohamed S. El-Okaily, Ahmed M. A. El‐Seidy,

Eman H. Ismail

et al.

Journal of materials research/Pratt's guide to venture capital sources, Journal Year: 2024, Volume and Issue: 39(12), P. 1741 - 1757

Published: April 30, 2024

Abstract Fabrications of nanomotors (NMs) are at the forefront exploring true potential nanotechnology. Tubular (TNMs) have been attracting huge interest recently. NMs based on 2D-hexagonal mesoporous silica (SBA-15) prepared through surfactant-assisted sol–gel method. Copper and/or iron oxide nanoparticles impregnated in SBA-15 to form catalytic tubular nanomotors. Characterization has investigated by XPS, XRD, HR-TEM, SEM–EDS, and BET. The electrochemical measurements were used confirm motion By increasing loading metal nanoparticles, decreases; this could be observed from current loss. anti-cancer synthesized against two cell lines (A549 H460) human lung carcinoma tested. Among all tested NMs, high-metal oxide-loaded materials containing CuO only as well Fe 2 O 3 potent significant apoptotic death for cancer treatment. Graphical abstract

Language: Английский

Citations

5
Caffeic acid ethanolamide induces antifibrosis, anti-inflammatory, and antioxidant effects protects against bleomycin-induced pulmonary fibrosis DOI Open Access
Cheng-Wei Huang,

Shih-Yi Lee,

Chen-Xuan Du

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 173, P. 116298 - 116298

Published: Feb. 23, 2024

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease; its cause unknown, it leads to notable health problems. Currently, only two drugs are recommended for IPF treatment. Although these can mitigate function decline, neither improve nor stabilize or the symptoms perceived by patients. Therefore, development of novel treatment options required. The present study investigated effects compound, caffeic acid ethanolamide (CAEA), on human fibroblasts evaluated potential bleomycin-induced in mice. CAEA inhibited TGF-β-induced α-SMA collagen expression fibroblasts, indicating that prevents from differentiating into myofibroblasts following TGF-β exposure. In animal studies, efficiently suppressed immune cell infiltration elevation TNF-α IL-6 bronchoalveolar lavage fluid mice with fibrosis. Additionally, exerted antioxidant recovering enzymatic activities oxidant scavengers. directly activation receptors protected against through inhibition TGF-β/SMAD/CTGF signaling pathway. protective effect was comparable pirfenidone, clinically available drug. Our findings support as viable method preventing progression

Language: Английский

Citations

4
Discovery of Potent Isoquinolinequinone N-Oxides to Overcome Cancer Multidrug Resistance DOI Creative Commons
Ryan D. Kruschel, Mélanie A. G. Barbosa, Maria João Almeida

et al.

Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 67(16), P. 13909 - 13924

Published: Aug. 2, 2024

Multidrug resistance (MDR) of human tumors has resulted in an immediate need to develop appropriate new drugs. This work outlines the development 20 potent IQQ N-oxide derivatives two isomeric families, both exhibiting nanomolar GI50 against tumor cell lines. Preliminary NCI-60 screening sees C(6) isomers achieve a mean > 2 times lower than corresponding C(7) isomers. MDR evaluation nine selected compounds reveals that each presents concentrations Four series display values cells, having selectivity ratios up 2.7 versus sensitive (parental) cells. The most compound 25 inhibits activity drug efflux pumps causes significant ROS accumulation, and potently proliferation, causing alterations cycle profile. Our findings are confirmed by 3D spheroid models, providing candidates for studies cancers.

Language: Английский

Citations

4
SLC2A1 boosts the resistance of non-small cell lung cancer to taxanes by stimulating the formation of EPCAM+ cancer stem-like cells via glycolysis DOI Creative Commons

Zhe Yu,

Jian Sun, Kai Fang

et al.

Translational Oncology, Journal Year: 2024, Volume and Issue: 49, P. 102082 - 102082

Published: Aug. 9, 2024

The mechanisms by which SLC2A1 enhances chemo-resistance of taxanes to non-small cell lung cancer (NSCLC) remains enigmatic.

Language: Английский

Citations

4
Efficacy of preoperative pulmonary rehabilitation in lung cancer patients: a systematic review and meta-analysis of randomized controlled trials DOI Creative Commons
Yinglu Guo, Ming Pan,

Meidi Xiong

et al.

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: Jan. 17, 2025

Although previous studies have shown that preoperative pulmonary rehabilitation training may improve postoperative prognosis in patients with lung cancer, the literature included existing meta-analysis is highly heterogeneous and lacks effective subgroup analysis. Therefore, an updated needed to integrate latest published randomized controlled clinical trials (RCT). This analysis was performed identify effects of on physical (lung function, activity endurance, dyspnea), psychological rehabilitation, quality life, length hospital stay, complications cancer. The PubMed, Embase, Cochrane Library, Web Science database were searched since inception up March 2024. A random-effects model used pool data, sensitivity analyses explore stability outcomes potential sources heterogeneity. All conducted via Review Manager 5.4.1 STATA 15.0. final 11 RCTs 1250 patients. results suggest can significantly life cancer after surgery (SMD: 0.16; 95% CI: 0.01, 0.32; P = 0.04) reduce risk (PPCs) (RR: 0.39; 0.25, 0.60; < 0.0001). suggested effect combined better than alone, short-term (≤ 3 weeks) long-term rehabilitation. Preoperative for their complications, but factors such as intervention time method affect effect.

Language: Английский

Citations

0
Special Issue: “Drug Repurposing for Cancer Therapies” DOI Open Access
Cristina P. R. Xavier, Andreia Palmeira

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(2), P. 1092 - 1092

Published: Jan. 16, 2024

Cancer is one of the primary global causes death, thus addressing cancer therapy remains a significant challenge, especially in cases where cancers exhibit resistance to treatment [...]

Language: Английский

Citations

3
Pitavastatin and Ivermectin Enhance the Efficacy of Paclitaxel in Chemoresistant High-Grade Serous Carcinoma DOI Open Access
Mariana Nunes, Diana Duarte, Nuno Vale

et al.

Cancers, Journal Year: 2022, Volume and Issue: 14(18), P. 4357 - 4357

Published: Sept. 7, 2022

Chemotherapy is a hallmark in high-grade serous carcinoma management; however, chemoresistance and side effects lead to therapeutic interruption. Combining repurposed drugs with chemotherapy has the potential improve antineoplastic efficacy, since can have independent mechanisms of action suppress different pathways simultaneously. This study aimed explore whether combination Paclitaxel led benefit. Thus, we evaluated cytotoxic alone several (Pitavastatin, Metformin, Ivermectin, Itraconazole Alendronate) two tumor chemoresistant (OVCAR8 OVCAR8 PTX R P) non-tumoral (HOSE6.3) cell lines. Cellular viability was assessed using Presto Blue assay, synergistic interactions were Chou-Talalay, Bliss Independence Highest Single Agent reference models. The Pitavastatin or Ivermectin showed highest effect strongest synergism among all combinations for both lines, resulting chemotherapeutic superior alone. Almost presented safe pharmacological profile cells. Overall, suggest that could act synergistically Paclitaxel, being promising two-drug management.

Language: Английский

Citations

11
Genes related to N6-methyladenosine in the diagnosis and prognosis of idiopathic pulmonary fibrosis DOI Creative Commons
Jingcheng Zhang, Ying Zhang, Ziyuan Wang

et al.

Frontiers in Genetics, Journal Year: 2023, Volume and Issue: 13

Published: Jan. 4, 2023

Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic disease with unknown etiology and poor outcomes. It severely affects the quality of life. In this study, we comprehensively analyzed expression N6-methyladenosine (m6A) RNA methylation regulators using gene data from various tissue sources in IPF patients healthy volunteers. Methods: The matrix clinical characteristics were retrieved Gene Expression Omnibus database. A random forest model was used to construct diagnosis signature m6A regulators. Regression analysis correlation identify prognosis Consensus cluster different risk groups, then functional enrichment, immune infiltration drug sensitivity performed. Result: Five candidate genes lung predict incidence, incidence validated datasets bronchoalveolar lavage fluid (BALF) peripheral blood mononuclear cells. Subsequently, BALF dataset containing outcomes for METTL14 , G3BP2 ZC3H13 independent protective factors. Using function tissue-derived dataset, factor IPF. Based on consensus applied distinguish prognostic regulation patterns. low-risk group’s significantly better than high-risk group. Biological processes regulated by groups included fibrogenesis cell adhesion. Analysis showed upregulation neutrophils five group sensitive drugs one identified. Discussion: These findings suggest that are involved IPF, patterns method

Language: Английский

Citations

6
CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model DOI Creative Commons
George Perez, Mauro Rosales, Ailyn C. Ramòn

et al.

Biomedicines, Journal Year: 2022, Volume and Issue: 11(1), P. 43 - 43

Published: Dec. 25, 2022

Large cell lung carcinoma (LCLC) is one form of NSCLC that spreads more aggressively than some other forms, and it represents an unmet medical need. Here, we investigated for the first time effect anti-CK2 CIGB-300 peptide in NCI-H460 cells as LCLC model. were highly sensitive toward cytotoxicity, reaching a peak apoptosis at 6 h. Moreover, slightly impaired cycle cells. The interactomics profile revealed 300 proteins many them participated biological processes relevant cancer. Interrogation CK2 subunits targeting by indicated higher binding to CK2α' catalytic subunit vivo pull-down assays plus immunoblotting analysis confocal microscopy. down-regulation both phosphorylation protein levels ribonuclear S6 (RPS6) was observed 48 h post treatment. Altogether, have found are most CIGB-300-sensitive solid tumor line described so far, also, findings provide here uncover novel features linked anticancer peptide.

Language: Английский

Citations

10